Shots: The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg, qd, PO) in a ratio (1:1) in 672 & 641 patients with HIV-1 who are virologically suppressed […]readmore
Tags : Trials
Shots: Takeda is providing rapid & sustained access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna. Earlier, Takeda has completed enrollment in the P-I/II study of TAK-919 […]readmore
Shots: The P-lll SURPASS-3 study involves assessing Tirzepatide (5/10/15 mg) vs titrated insulin degludec in 1444 participants in a ratio (1:1:1:1) with T2D treated with metformin with or without an […]readmore
Shots: The company reported that the COVID-19 vaccine is safe, well-tolerated & immunogenic in the P-I/II study & plans to initiate P-III clinical trial in ~30000 volunteers upon receiving necessary […]readmore
Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s […]readmore
Shots: AstraZeneca has resumed the clinical trial of AZD1222 in the UK, following the MHRA’s confirmation that it is safe to resume the trial On Sept 06, 2020, the standard […]readmore
Shots: The two P-III studies, ASCLEPIOS I & II involves assessing of ofatumumab (20mg, monthly SC) vs teriflunomide (14mg) in 1882 patients aged 18-55yrs with MS and EDDS score b/w […]readmore
Shots: The two P-III trials SGT-65-04 and SGT-65-05 involves assessing of Twyneo (qd) or vehicle cream in 858 patients in ratio (2:1) at 63 sites for 12 wks. The P-III […]readmore
Shots: The P-III reSURFACE 1 and 2 are extension-study involves assessing of Ilumya (100 &200 mg at 0 and 4wks.) and Ilumya (100 & 200 mg) vs PBO and etanercept […]readmore
Shots: The P-III CREAD-1 and 2 study involves assessing of Crenezumab vs PBO in 1500 patients with early AD with confirmed evidence of cerebral beta-amyloid pathology (CSF or amyloid PET) […]readmore